U.S. markets close in 1 hour 19 minutes
  • S&P 500

    4,168.45
    +43.79 (+1.06%)
     
  • Dow 30

    34,027.41
    +296.52 (+0.88%)
     
  • Nasdaq

    14,030.97
    +173.13 (+1.25%)
     
  • Russell 2000

    2,254.75
    +7.04 (+0.31%)
     
  • Crude Oil

    63.36
    +0.21 (+0.33%)
     
  • Gold

    1,766.80
    +30.50 (+1.76%)
     
  • Silver

    25.99
    +0.46 (+1.81%)
     
  • EUR/USD

    1.1979
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.5340
    -0.1040 (-6.35%)
     
  • GBP/USD

    1.3791
    +0.0010 (+0.07%)
     
  • USD/JPY

    108.6370
    -0.2900 (-0.27%)
     
  • BTC-USD

    63,068.90
    -26.60 (-0.04%)
     
  • CMC Crypto 200

    1,384.15
    +3.20 (+0.23%)
     
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • Nikkei 225

    29,642.69
    +21.70 (+0.07%)
     

Is Akari Therapeutics, Plc (NASDAQ:AKTX) Popular Amongst Insiders?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Akari Therapeutics, Plc (NASDAQ:AKTX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

With a market capitalization of US$100m, Akari Therapeutics is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutional investors have not yet purchased much of the company. Let's delve deeper into each type of owner, to discover more about Akari Therapeutics.

View our latest analysis for Akari Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Akari Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Less than 5% of Akari Therapeutics is held by institutional investors. This suggests that some funds have the company in their sights, but many have not yet bought shares in it. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Akari Therapeutics. RPC Pharma Limited is currently the largest shareholder, with 21% of shares outstanding. With 18% and 3.2% of the shares outstanding respectively, Aspire Capital Partners, LLC and Yasumitsu Shigeta are the second and third largest shareholders.

Our studies suggest that the top 21 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Akari Therapeutics

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

We can see that insiders own shares in Akari Therapeutics, Plc. In their own names, insiders own US$6.3m worth of stock in the US$100m company. It is good to see some investment by insiders, but I usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

General Public Ownership

The general public -- mostly retail investors -- own 51% of Akari Therapeutics. With this size of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to decline an acquisition or merger that may not improve profitability.

Private Equity Ownership

Private equity firms hold a 18% stake in Akari Therapeutics. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Private Company Ownership

Our data indicates that Private Companies hold 21%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Akari Therapeutics (at least 2 which make us uncomfortable) , and understanding them should be part of your investment process.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.